Shots:

• The approval is based in P-III JAVELIN Renal 101 study assessing Bavencio + Axitinib vs Sunitinib in 886 patients with untreated advanced or metastatic RCC with all IMDC prognostic risk groups and irrespective of PD-L1 expression
• The P-III JAVELIN Renal 101 study resulted in improvement in PFS (13.3 vs 8.0 mos.) with a median follow-up for OS is 19mos. The EC’s approval follows the FDA’s approval of Bavencio + Axitinib for 1L treatment of advanced RCC in May’2019
• Bavencio is an anti-PD-L1 antibody- act by blocking the interaction of PD-L1 with PD-1 receptors- demonstrating T cell-mediated antitumor immune response suppression in preclinical models. In Nov’2014- Merck KGaA & Pfizer collaborated to co-develop & co-commercialize Bavencio

Click here to­ read full press release/ article | Ref: Pfizer | Image: The Times